Vitamin B6-Coupled Polydixylitol Gene Transporter for Brain Tumor Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene delivery methods face challenges in targeting and efficiently delivering nucleic acids to cancer stem cells, particularly in glioblastoma multiforme, due to the blood-brain barrier's impermeability and the limitations of viral and non-viral vectors, including low transfection efficiency and cytotoxicity.
Innovation Solution
A vitamin B6-coupled polydixylitol polymer gene transporter (VBXYP-P) is developed, which incorporates a cancer stem cell-targeting peptide (TR-7) and uses a Sulfo-SANPAH linker to enhance permeability and reduce cytotoxicity, allowing for efficient delivery of therapeutic nucleic acids across the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional gene delivery methods are used, then nucleic acids can be delivered to cells, but the delivery efficiency to cancer stem cells is low and cytotoxicity occurs
Solution Approach 1:
The patent uses a composite polymer structure combining polydixylitol backbone with peptide targeting moieties and vitamin B6 coupling. This composite material achieves both high nucleic acid delivery efficiency to cancer stem cells and minimal cytotoxicity, resolving the contradiction between productivity and harmful effects.
Solution Approach 2:
The gene transporter is designed with localized functional regions: the polydixylitol backbone provides biocompatibility, peptide sequences provide cancer stem cell-specific targeting, and vitamin B6 coupling enhances permeability. This local quality differentiation enables high delivery efficiency to target cells while maintaining low cytotoxicity to normal cells.
2Reliability
If the blood-brain barrier is crossed to deliver genes to brain tumors, then therapeutic effect is improved, but delivery difficulty increases due to impermeability
Solution Approach 1:
Vitamin B6 acts as an intermediary that facilitates blood-brain barrier permeation. The vitamin B6-coupled polydixylitol transporter uses the vitamin's ability to cross the blood-brain barrier via active transport mechanisms, thereby mediating the delivery of therapeutic nucleic acids to brain tumor cells without requiring complex delivery systems.
Solution Approach 2:
The patent modifies the chemical and physical parameters of the gene transporter by coupling vitamin B6 to the polydixylitol backbone. This parameter change enables the transporter to exploit vitamin B6 transport pathways in the blood-brain barrier, transforming the delivery mechanism from passive diffusion to active transport-mediated delivery.
3Measurement precision
If cancer stem cells are targeted specifically, then therapeutic precision is improved, but targeting complexity increases
Solution Approach 1:
The patent integrates multiple functions into a single gene transporter molecule: the polydixylitol backbone provides biocompatibility and nucleic acid binding, peptide sequences provide cancer stem cell targeting, and vitamin B6 coupling provides blood-brain barrier permeation. This multi-functionality in a single molecule achieves high targeting precision without requiring complex multi-component systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
VBXYP-P demonstrates significantly higher nucleic acid delivery rates to cancer stem cells with minimal cytotoxicity, effectively inhibiting cancer stem cell expression and inducing apoptosis, while permeating the blood-brain barrier to target glioblastoma multiforme cells.
Implementation Method 1
a peptide (TR-7 peptide) binding specifically to a CD133 protein that is a marker for cancer stem cells
Implementation Method 2
a nucleic acid delivery complex in which a therapeutic nucleic acid is electrostatically bound to the gene transporter
Data Source
AI summary
Provided is a polydixylitol polymer gene transporter (VBXYP-P) containing vitamin B6 and a cancer stem cell-targeting peptide (TR-7) and a method for preparing the same. In addition, provided is a nucleic acid delivery complex in which a therapeutic nucleic acid is conjugated to the gene transporter, and a pharmaceutical composition for gene therapy containing the complex as an active ingredient. In addition, provided is the gene transporter, a gene delivery complex, and gene therapy using the same. It was observed that VBXYP-P of the present disclosure had a remarkably higher nucleic acid delivery rate to cancer stem cells than the pre-existing nucleic acid transporter, and when VBXYP-P was conjugated with DNA, the complex was almost free of cytotoxicity and permeated a blood brain barrier to exhibit remarkably high transformation efficiency for cancer stem cells inside a brain tumor.